MedTrace Logo

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

NCT06159062 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-07-16

No results posted yet for this study

Summary

The goal of this intervention research is to learn about the safety and tolerability of 162 with a single ascending dose in subjects with chronic hepatitis B virus (HBV) infection.

Conditions

  • Chronic Hepatitis B Virus Infection

Interventions

DRUG

162

The investigational product 162 is a novel monoclonal antibody targeting HBsAg.

DRUG

Placebo

Placebo do not consist any active ingredients.

Sponsors & Collaborators

  • Yangshengtang Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-03
Primary Completion
2024-07-09
Completion
2024-07-09

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159062 on ClinicalTrials.gov